William Pierceall
Executive Director, Early Oncology Translational Development Pfizer
William Pierceall is currently a Executive Director, Early Oncology Translational Lead at Pfizer. William Pierceall brings experience from previous roles at Bristol Myers Squibb, Celgene and Roche. William Pierceall holds a Postdoctoral research in Cancer Biology/Translational Biology at Yale University. With a robust skill set that includes Drug Discovery, High Throughput Screening, Purification, Biochemistry, Assay Development and more.
Seminars
Wednesday 22nd July 2026
Panel Discussion: Leveraging Methylation-Based Liquid Biopsies to Deliver Earlier, More Actionable Trial Signals
9:30 am
- Where can methylation-based liquid biopsy create tangible impact in drug development today?
- Can methylation enable earlier and more confident clinical trial decision-making?
- What must happen for methylation to become embedded in mainstream clinical trial design?
Moderated by:
Wednesday 22nd July 2026
Panel Discussion: Integrating Emerging Diagnostic Technologies to Enable Faster, More Informed Clinical Development
4:30 pm
- How to integrate emerging diagnostics, including liquid biopsy, with complimentary modalities to generate earlier, higher confidence clinical signals
- What is required to make these technologies decision-grade at scale, including validation, standardization, and operational workflows
- Where integration most accelerates development, improving patient selection, response monitoring, and resistance insight to deliver better therapies faster
